Abstract 492P
Background
Surgery is one of the necessary treatment methods for breast cancer patients. However, wound caused by surgery is the main source of clinically related stress stimulation, and can promote tumor metastasis. Currently, as an important component of the tumor microenvironment, myeloid-derived suppressor cells (MDSC) have become a hotspot in the study of tumor metastasis.
Methods
We comprehensively explored the influence of wound stress on tumor growth, EMT related metastasis, and the recruitment of MDSC in the tumor microenvironment in a subcutaneous 4T1 tumor model.
Results
We found that wound stress stimulation promoted breast cancer growth and lung metastasis in mice, and enhanced the recruitment of stressed MDSC in the tumor microenvironment. The expression of Vimentin increased, suggesting EMT transformation. In vitro, bone marrow MDSC cells from mice undertaking stress stimulation promoted the EMT transformation in 4T1. The exosomes were extracted and the expression of mmu-miR-126a-5p was low in stressed MDSC exosomes. Mmu-miR-126a-5p overexpression suppressed tumor growth, lung metastasis and EMT transformation. Through the database screening of the target gene of mmu-miR-126a-5p combined with the results of sequencing analysis, CXCL12 was predicted to be the target gene of mmu-miR-126a-5p, which was verified by double luciferase reporting assay. CXCL12 and CXCR4 were highly expressed in the wound stress stimulation model, indicating mmu-miR-126a-5p induces breast cancer EMT transformation by targeting CXCL12/CXCR4 axis.
Conclusions
Here, we found that surgical stress stimulation can elicit the recruitment of stressed MDSC in the tumor microenvironment. Reduced exosome miR-126a-5p released by stressed MDSC leads to EMT transformation of tumor cells by attenuating the inhibition of CXCL12/CXCR4 axis in 4T1 cells and ultimately promotes increased lung metastasis. From the perspective of tumor microenvironment, these findings explain the phenomenon of increased lung metastasis caused by surgical stress stimulation and optimize new targets for MDSC, thus providing new ideas for breast cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
447P - Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: A systematic review and meta-analysis
Presenter: Lixi Li
Session: Poster session 04
448P - Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
Presenter: Hossameldin Abdallah
Session: Poster session 04
449P - Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study
Presenter: Claudia von Arx
Session: Poster session 04
450P - A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2-negative advanced breast cancer
Presenter: Ying Zhang
Session: Poster session 04
451P - Breast Cancer Lighthouse study: 1 year follow-up results of ribociclib treatment patterns and clinical outcomes in a real-world Portuguese cohort
Presenter: Beatriz Gosalbez Pequeno
Session: Poster session 04
452P - A phase II trial of anlotinib and fulvestrant in patients with metastatic breast cancer previously treated with an aromatase inhibitor
Presenter: Xiaojia Wang
Session: Poster session 04
453P - Clinical outcomes of pyrotinib-based therapy after prior trastuzumab and pertuzumab in HER2-positive metastatic breast cancer
Presenter: Jinmei Zhou
Session: Poster session 04
454P - Real-world genomic profiling of patients with advanced or metastatic triple-negative breast cancer in the UK and EU4: A systematic literature review
Presenter: Barinder Singh
Session: Poster session 04
455P - Post progression treatments after endocrine therapy (ET) plus palbociclib in patients with HR+/HER2- metastatic breast cancer (MBC): A prospective, real-world study
Presenter: Raffaella Palumbo
Session: Poster session 04